Vyome Holdings, IncHINDEarnings & Financial Report
Vyome Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutic solutions for a range of dermatological conditions. Its product pipeline targets unmet medical needs related to acne, atopic dermatitis, and chronic fungal infections, with primary operations and market presence across North America and South Asia.
Revenue
$1.8M
Gross Profit
$-2.1M
Operating Profit
N/A
Net Profit
$2.9M
Gross Margin
-118.6%
Operating Margin
N/A
Net Margin
160.0%
YoY Growth
-8.9%
EPS
$-4355.36
Vyome Holdings, Inc Q4 FY2024 Financial Summary
Vyome Holdings, Inc reported revenue of $1.8M (down 8.9% YoY) for Q4 FY2024, with a net profit of $2.9M (up 270.1% YoY) (160.0% margin). Cost of goods sold was $3.9M.
Key Financial Metrics
| Total Revenue | $1.8M |
|---|---|
| Net Profit | $2.9M |
| Gross Margin | -118.6% |
| Operating Margin | N/A |
| Report Period | Q4 FY2024 |
Vyome Holdings, Inc Annual Revenue by Year
Vyome Holdings, Inc annual revenue history includes year-by-year totals (for example, 2024 revenue was $8.0M).
| Year | Annual Revenue |
|---|---|
| 2024 | $8.0M |
| 2023 | $8.7M |
| 2022 | $11.2M |
Vyome Holdings, Inc Quarterly Revenue & Net Profit History
Vyome Holdings, Inc results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 FY2025 | $1.2M | -36.8% | $-2.6M | -211.8% |
| Q1 FY2025 | $1.1M | -42.7% | $1.5M | 132.4% |
| Q4 FY2024 | $1.8M | -8.9% | $2.9M | 160.0% |
| Q3 FY2024 | $2.3M | +6.4% | $-547.8K | -23.9% |
| Q2 FY2024 | $2.0M | -12.8% | $-1.6M | -81.2% |
| Q1 FY2024 | $1.9M | -15.0% | $-2.2M | -112.8% |
| Q4 FY2023 | $2.0M | -36.3% | $-1.7M | -85.7% |
| Q3 FY2023 | $2.2M | -23.0% | $-3.5M | -164.0% |
Income Statement
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.2M | $2.0M | $1.9M | $2.0M | $2.3M | $1.8M | $1.1M | $1.2M |
| YoY Growth | -23.0% | -36.3% | -15.0% | -12.8% | 6.4% | -8.9% | -42.7% | -36.8% |
Balance Sheet
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $7.8M | $10.7M | $8.2M | $-613992 | $1.3M | $1.4M | $6.5M | N/A |
| Liabilities | $4.7M | $4.0M | $3.7M | $3.4M | $4.1M | $5.8M | $5.3M | N/A |
| Equity | $3.1M | $-6.2M | $4.5M | $-4.0M | $1.5M | $-4.4M | $1.2M | $-5.0M |
Cash Flow
| Q3 2023 | Q4 2023 | Q1 2024 | Q3 2024 | Q1 2025 | |
|---|---|---|---|---|---|
| Operating CF | $-2.8M | $-2.5M | $-2.1M | $1.5M | $-2.1M |